In contrast, use of GlcN to increase O-GlcNAcylated protein levels decreased AKT activity in circulating CLL cells, evidenced by diminished size and lowered phosphorylation at Thr308 (2). Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.